At Ocusight Pharma, we develop breakthrough ophthalmic therapeutics that restore, preserve, and enhance vision. Our science meets compassion in every formulation.
As a certified ISO 9001:2015 and FDA-compliant eye drop trading company, we are committed to delivering premium-quality ophthalmic products that meet the highest standards of safety, effectiveness, and reliability. Quality assurance is at the core of our operations, ensuring that every product reaches customers in optimal condition.
From research to patient access, we deliver excellence across the entire ophthalmic care spectrum.
Cutting-edge molecular research targeting retinal diseases, glaucoma, and degenerative eye conditions through novel therapeutic pathways.
Rigorous Phase I-IV clinical development programs conducted to the highest international standards with global trial networks.
State-of-the-art sterile manufacturing facilities producing preservative-free ophthalmic solutions with advanced aseptic processing.
Expert navigation of global regulatory pathways ensuring rapid market access across FDA, EMA, and emerging markets.
Comprehensive training programs for healthcare professionals on latest therapeutic approaches and treatment protocols.
Dedicated patient assistance programs ensuring access to life-changing therapies through financial and educational support.
Discover our range of innovative ophthalmic products designed to treat various eye conditions.
Novel anti-VEGF therapy for wet age-related macular degeneration with extended dosing intervals.
Next-generation prostaglandin analog for elevated intraocular pressure with improved ocular tolerability.
Innovative immunomodulatory therapy for chronic dry eye disease targeting inflammatory pathways.
Hear from leading ophthalmologists and healthcare professionals who partner with Ocusight.
"OcuLucent™ has transformed the way we treat wet AMD. The extended durability allows our patients fewer injections with outstanding visual outcomes."
"GlauCare® offers unparalleled IOP control with minimal side effects. It's become our first-line therapy for newly diagnosed glaucoma patients."
"The clinical trial support from Ocusight is exceptional. Their commitment to rigorous science and patient safety sets them apart in the industry."
"As a researcher in dry eye disease, TearSyn's mechanism of action represents a true breakthrough. I'm excited to see its impact on patient quality of life."